

A. Dimitrios Colevas
CURRICULUM VITAE

Date Prepared: 4/27/2007

Name: Alexander Dimitrios Colevas

Office Address: Stanford Cancer Center
875 Blake Wilbur Drive
Stanford, CA 94305-5820
(650) 724-9707

Education:

1985	B.A.	Columbia University, New York, NY
1989	M.D.	Johns Hopkins University School of Medicine, Baltimore, MD

Postdoctoral Training:

1989-90	Intern in Medicine, Johns Hopkins Hospital, Baltimore, MD
1990-92	Resident, Internal Medicine, Johns Hopkins Hospital
1993-95	Fellow in Medical Oncology, Dana-Farber Cancer Institute
1993-95	Clinical Fellow in Medicine, Harvard Medical School
1993-95	Clinical Fellow in Medicine, Brigham and Women's Hospital

Licensure and Certification:

1991	Maryland Medical license # D41602
1992	American Board of Internal Medicine Certificate
1992	Alaska Medical license #2853
1993	Massachusetts Medical license #77185
1995	American Board of Internal Medicine, Medical Oncology Certificate
2002	American Board of Internal Medicine Recertification 144692
2002	American Board of Internal Medicine, Medical Oncology Recertification 144692

Academic Appointments:

1995	Instructor in Medicine, Harvard Medical School
2000	Assistant Professor in Medicine, Harvard Medical School
2007	Associate professor of Medicine , Stanford Medical School

Governmental appointments and assignments

2001-	Senior Investigator, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute
2006	Senior Reviewer for Head and Neck Cancer, Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute

2006-	NCI voting representative, Clinical Trials Working Group Head and Neck Cancer Steering Committee
-------	--

Hospital or Affiliated Institution Appointments:

1992-93	Internist, Tanana Valley Clinic, Fairbanks, AK
1992-93	Attending Physician, Fairbanks Memorial Hospital, Fairbanks, AK
1996-2000	Associate, Head and Neck Oncology Program, Dana-Farber Cancer Institute
1996-2000	Attending Physician, Division of Hematology/Oncology, Brigham and Women's Hospital
1997-2000	Medical Staff, Beth Israel Deaconess Medical Center
2000	Senior Investigator, Investigational Drug Branch, National Cancer Institute
2000	Multidisciplinary Head and Neck Cancer Clinic, NIDCD/NIH
2007	Member, Stanford Cancer Center

Major Committee Assignments:

Affiliated Institutions

1996-2000	Head and Neck Clinical Practice Guidelines Committee, Dana-Farber/Partners Cancer Care
1997-2000	Head and Neck Research Committee, Dana-Farber/Partners Cancer Care
1989-2000	Phase I Clinical trials Working Group, Dana-Farber/Partners Cancer Care

National

1998-2000	National Comprehensive Cancer Network Head and Neck Cancer Panel
1999-2000	Radiation Therapy Oncology Group Chemoprevention Committee
2001-	Chair, Common Toxicity Criteria Development Team, NCI
2001	Member, NCI Special Emphasis Panel for R13 review, NCI
2002	Co- Chair, Radiation Modifier Working Group, NCI
2005	Trans-NIH Adverse Event Steering Committee
2005-	CTEP representative, CTCAE- MedRA harmonization/ translation project
2006-	NCI voting representative, Clinical Trials Working Group Head and Neck Cancer Steering Committee

Professional Societies:

1993-2000	American Medical Association
1996-2000	American Society of Clinical Oncology
1997-2000	French Federation of Medical Oncologists # 970150
1997-2000	Massachusetts Society of Clinical Oncologists
1998-2000	Radiation Therapy Oncology Group

Editorial Boards:

1997-	Ad Hoc Reviewer, Journal of Clinical Oncology
1999-	Ad Hoc Reviewer, Head and Neck
1999-	Ad Hoc Reviewer, Clinical Cancer Research
2003-	Ad Hoc Reviewer, Cancer Chemotherapy and Pharmacology
2003-	Ad Hoc Reviewer, Oncology
2004-	Ad Hoc Reviewer, Review of Proteomics
2004-	Ad Hoc Reviewer, International Journal of Cancer
2006 -	Ad Hoc Reviewer, Cancer

Awards and Honors:

1985	Cum Laude, Columbia College, New York, NY
1995	Ladies Auxiliary to the Veterans of Foreign Wars Fellowship
1996	KO8 Award, National Institutes of Health
2004	NIH Merit Award for CTC AE v 3 development
2006	NIH Merit Award for development and implementation of a clinical trial management system

Regional, national, or international contributions:

1. Invited speaker :

1996	Vassar Brothers Hospital, Poukeepsie, New York
1997, 1998	Invited speaker, Seventh International Congress on Anti-Cancer Treatment, Paris, France
1997	University of Virginia division of medical oncology, Charlottesville, VA.
1998	Chemotherapy Foundation Symposium XV, New York City, NY.
1998	U.T. MD Anderson Cancer Center division of medical oncology, Houston, TX.
1998,1999	University of Maryland Greenbaum Cancer Center Oncology Grand Rounds, Baltimore, MD.
1998	Glens Falls Cancer Center, New York. Oncology Grand Rounds
2000	September: Oncology grand rounds, Midland Memorial Hospital, Midland, TX
2000	Guest speaker, Annual meeting American Society for Radiation and Oncology, Boston MA
2001-	Guest speaker, Radiation oncology cooperative group semi- annual meetings
2004	Invited discussant, American Society of Clinical Oncology Annual meeting.
2004	Invited speaker, AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
2005	Invited Speaker, American Society for Therapeutic Radiology and Oncology annual meeting

2. 1998-2000: Member, National Comprehensive Cancer Network (NCCN) Head and Neck Cancer Panel. The NCCN is a consortium of 14 regional U.S. cancer centers. Panels were created to develop evidence-based practice guidelines for the treatment of specific neoplasms, in order to define a uniformly accepted standard of care both within the network and as an example for the greater oncology community. Dr. Colevas has actively participated in the formulation and ongoing updates of the head and neck cancer practice guidelines.
3. 1998 Joint ASCO/AACR Workshop in Clinical Cancer Research Junior Faculty.
4. 2003- Chair, program planning, NCI CTEP semi- annual early clinical trials meeting.
5. 2006 Co- chair, NCI Salivary gland cancer workshop.

Report of Clinical Activities:

1995-2000. General medical oncologist, Brigham and Women's Hospital Division of Hematology/Oncology. Dr. Colevas cared for general oncology patients as an attending oncologist at the BWH site until the closure of this site occasioned by the merger of the DFCI and BWH oncology programs. During this time he was responsible for staffing 4 half-day clinics weekly to care for his own patients and to supervise the BWH medical oncology fellows. Following the merger of the DCI and BWH oncology programs, Dr Colevas provided longitudinal care for a cohort of general oncology patients.

1995-2000. Medical oncologist, DFCI Head and Neck Oncology Program (HNOP). Dr. Colevas participated in this tertiary referral program. His three areas of clinical focus included:

1. Multimodality curative treatment of patients with locoregionally advanced head and neck squamous cell cancers.
2. Treatment of patients with metastatic and locoregionally advanced salivary gland neoplasms.
3. Evaluation and treatment of patients with metastatic squamous cell carcinoma or squamous cell carcinoma of unknown primary site.

2000- present Medical Oncologist, National Institute on Deafness and other Communication Disorders, NIH Clinical Center. Dr Colevas provides consultative services and ongoing evaluation and care as part of a multi-modality team in the head and neck cancer clinic at the NIDCD .

BIBLIOGRAPHY

Original Articles, peer reviewed

1. **Colevas** AD, Edwards JL, Hruban RH, Mitchell GA, Valle D, Hutchins GM: Glutaric acidemia type II. Comparison of pathologic features in two infants. Arch Pathol Lab Med 112:1133-9, 1988
2. Clark JR, Busse PM, Norris CM, Jr., Andersen JW, Dreyfuss AI, Rossi RM, Poulin MD, **Colevas** AD, Tishler RB, Costello R, Lucarini JW, Lucarini D, Thornhill L, Lackey M, Peters E, Posner MR: Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 15:3100-10, 1997
3. Bhattacharyya N, Norris CM, **Colevas** AD, Chasse TA: Intramucosal spread of malignant melanoma of the oral cavity. Otolaryngol Head Neck Surg 119:711, 1998
4. **Colevas** AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR: Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 16:1331-9, 1998.
5. Posner MR, Johnston PG, Tishler RB, Andersen J, Fiorentino M, Busse PM, Cavacini LA, **Colevas** AD, Clark J, Norris CM: The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck. Oncologist 3:424-431, 1998
6. **Colevas** AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, Nixon A, Lamb C, Costello R, Barton J, Read R, Adak S, Posner MR: Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17:3503-11, 1999
7. Tishler RB, Busse PM, Norris CM, Jr., Rossi R, Poulin M, Thornhill L, Costello R, Peters ES, **Colevas** AD, Posner MR: An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys 43:1001-8, 1999
8. **Colevas** AD, Adak S, Amrein PC, Barton JJ, Costello R, Posner MR: A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Ann Oncol 11:535-9, 2000
9. Posner MR, **Colevas** AD, Tishler RB: The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol 27:13-24, 2000
10. Pfister DG, Ang K, Brockstein B, **Colevas** AD, Ellenhorn J, Goepfert H, Hicks WL, Jr., Hong WK, Kies MS, Lydiatt W, McCaffrey T, Mittal BB, Ridge JA, Schuller DE, Shah

JP, Spencer S, Trotti A, 3rd, Urba S, Weymuller EA, Jr., Wheeler RH, 3rd, Wolf GT: NCCN Practice Guidelines for Head and Neck Cancers. Oncology (Williston Park) 14:163-94, 2000

11. **Colevas** AD, Amrein PC, Gomolin H, Barton JJ, Read RR, Adak S, Benner S, Costello R, Posner MR: A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. *Cancer* 92:326-31, 2001
12. **Colevas** AD, Read R, Thornhill J, Adak S, Tishler R, Busse P, Li Y, Posner M: Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. *Int J Radiat Oncol Biol Phys* 51:599-604, 2001
13. Posner MR, Glisson B, Frenette G, Al-Sarraf M, **Colevas** AD, Norris CM, Seroskie JD, Shin DM, Olivares R, Garay CA: Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. *J Clin Oncol* 19:1096-104, 2001
14. **Colevas** AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, Gopal HV, Costello R, Read R, Adak S, Posner MR: Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). *Am J Clin Oncol* 25:153-9, 2002
15. Tishler RB, Norris CM, Jr., **Colevas** AD, Lamb CC, Karp D, Busse PM, Nixon A, Frankenthaler R, Lake-Willcutt B, Costello R, Case M, Posner MR: A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. *Cancer* 95:1472-81, 2002
16. Haddad R, **Colevas** AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. *Oral Oncol* 39:724-7, 2003
17. Haddad R, **Colevas** AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M: Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. *Cancer* 97:412-8, 2003
18. Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, Mann DL, Nakanishi T, Wright JJ, **Colevas** AD: Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. *Clin Cancer Res* 9:307-15, 2003
19. Trotti A, **Colevas** AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol* 13:176-81, 2003
20. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, **Colevas** AD, Eisenhauer EA: Phase II trial of flavopiridol, a cyclin dependent kinase

inhibitor, in untreated metastatic malignant melanoma. *Invest New Drugs* 22:315-22, 2004

21. Glisson B, **Colevas AD**, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M: HER2 expression in salivary gland carcinomas: dependence on histological subtype. *Clin Cancer Res* 10:944-6, 2004
22. Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, **Colevas AD**, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF: Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. *Cancer* 104:1418-27, 2005
23. Gadgeel SM, Wozniak A, Boinpally RR, Wiegand R, Heilbrun LK, Jain V, Parchment R, **Colevas D**, Cohen MB, LoRusso PM: Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. *Clin Cancer Res* 11:6233-9, 2005
24. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, **Colevas AD**, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK: Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. *J Clin Oncol* 23:1439-46, 2005
25. Hussain M, Tangen CM, Lara PN, Jr., Vaishampayan UN, Petrylak DP, **Colevas AD**, Sakr WA, Crawford ED: Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. *J Clin Oncol* 23:8724-9, 2005
26. Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, **Colevas AD**, Bauer KS: Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. *Clin Cancer Res* 11:8403-12, 2005
27. Rudek MA, Zhao M, Smith NF, Robey RW, He P, Hallur G, Khan S, Hidalgo M, Jimeno A, **Colevas AD**, Messersmith WA, Wolff AC, Baker SD: In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. *Clin Cancer Res* 11:8503-11, 2005
28. Trump, D. L. Galsky, MD, Small EJ, Oh WK, Chen I, Smith DC, **Colevas AD**, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK, "Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer Memorial Sloan-Kettering Cancer Center, New York, NY." *Urol Oncol* 23(5): 378. (2005).
29. Scharf O, **Colevas AD**. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. *J Clin Oncol* 2006;24(24):3933-8.

30. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins C, **Colevas AD**, Donehower RC, Carducci MA, Wolff AC. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. *Eur J Cancer* 43:78-86, 2007.
31. Mani S, McDaid HM, Grossman A, Muggia F, Goel S, Griffin T, **Colevas D**, Horwitz SB, Egorin MJ. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. *Ann Oncol* 18:190-5, 2007
32. Beekman KW, **Colevas AD**, Cooney K, DiPaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer. *CLIN GENITOURIN CANC* 4 (4): 299-302 MAR 2006
33. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, **Colevas AD**, Grever MR. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. *Blood* 109:399-404, 2007.
34. Burt Nabors, Tom Mikkelsen, Steven S Rosenfeld, Fred Hochberg, Shastry Akella, Joy D. Fisher, Cloud Gretchen, Yu Zhang, Kathryn Carson, Sabine M Wittemer, **Dimitrios Colevas**, and Stuart A Grossman. A Phase I and Correlative Biology Study of Cilengitide in Patients with Recurrent Malignant Glioma. *Journal of Clinical Oncology* 2007 May 1;25(13):1651-7
35. O' Connor O, Portlock C, Moskowitz C, Straus D, Hamlin P, Neylon E, Butos J, MacGregor-Cortelli B, Pappanicolou J, Sarasohn D, Dumetrescu O, **Colevas A**, Zelenetz A, Grant B. A multicenter phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS 247550) in patients with indolent non- hodgkin's lymphoma and mantle cell lymphoma. submitted, *Journal of Clinical Oncology* 2006.
36. Martee L. Hensley, Don Dizon, Felicia Derosa, Ennapadam Venkatraman, Paul Sabbatini, Dennis S. Chi, Jakob Dupont, **A. Dimitrios Colevas**, David Spriggs and Carol Aghajanian. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. [Invest New Drugs](#). 2007 Mar 16; [Epub ahead of print]
37. Edwin M. Posadas, Samir Undevia, Elizabeth Manchen, James L. Wade, Dimitrios Colevas, Theodore Karrison, Everett E. Vokes and Walter M. Stadler. A Phase II Study of Ixabepilone (BMS-247550) in Metastatic Renal-Cell Carcinoma. [Cancer Biol Ther.](#) 2007 Apr 8;6(4) [Epub ahead of print]

Review Articles.

1. Posner MR, **Colevas** AD: Induction chemotherapy in the management of squamous cell cancer of the head and neck. *Cancer J Sci Am* 3:73-5, 1997
2. **Colevas** AD: Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT. *Oncology (Williston Park)* 11:86-9, 1997
3. **Colevas A**: Docetaxel in squamous cell carcinoma of the head and neck. *Cancer Investigation* 17:62-63, 1998.
4. **Colevas** AD, Posner MR: Docetaxel in head and neck cancer: a review. *Am J Clin Oncol* 21:482-6, 1998.
5. **Colevas** AD, West PJ, Cheson BD: Clinical trials referral resource. Current clinical trials of epothilone B analog (BMS-247550). *Oncology (Williston Park)* 15:1168-9, 1172-5, 2001.
6. **Colevas** D, Blaylock B, Gravell A: Clinical trials referral resource. Flavopiridol. *Oncology (Williston Park)* 16:1204-5, 1210-2, 1214, 2002.
7. **Colevas** AD, Brown JM, Hahn S, Mitchell J, Camphausen K, Coleman CN: Development of investigational radiation modifiers. *J Natl Cancer Inst* 95:646-51, 2003
8. **Colevas** AD: Organ preservation-induction chemotherapy. *Cancer Treat Res* 114:213-34, 2003.
9. Mani S, Macapinlac M, Jr., Goel S, Verdier-Pinard D, Fojo T, Rothenberg M, **Colevas** D: The clinical development of new mitotic inhibitors that stabilize the microtubule. *Anticancer Drugs* 15:553-8, 2004
10. **Colevas** AD, Scharf O, Schoenfeldt M: Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent. *Oncology (Williston Park)* 18:1778, 1781-2, 1784, 2004
11. **Colevas AD**. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. *J Clin Oncol* 2006;24(17):2644-52.

Editorials

12. **Colevas** AD: Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck 20: 758-762, 1998). *Head Neck* 21:582, 1999

Book Chapters

13. **Colevas A**, Kantoff P, Wolfe WD, 1140-1151. GC: Malignant Lymphoma of the Genitourinary Tract, in Vogelzang N, Scardino P, Shipley W, Coffey D (eds): Comprehensive Textbook of Genitourinary Oncology (ed 1). Baltimore, Williams and Wilkins, 1996, pp 1140-518.
14. **Colevas A**. Head and Neck Cancer. In: Skarin A, ed. Oncology Board Review Manual, vol. 3 part 4, ed. Hospital Physician, 1999; 1-14.
15. **Colevas A**, Kantoff P, Wolfe WD, Canellos G: Malignant Lymphoma of the Genitourinary Tract, in Vogelzang N, Scardino P, Shipley W, Coffey D (eds): Comprehensive Textbook of Genitourinary Oncology (ed 2). Baltimore, Williams and Wilkins, 2000, pp 1120-1133
16. **Colevas A**: Tumor Response Evaluation in Clinical Trials: RECIST, in Budman, Calvert, Rowinsky (eds): Handbook of Anticancer Drug Development. Baltimore, Lippincott Williams and Wilkins, 2003, pp 331-341.
17. **Colevas AD**, Clark J, Suojanen JN, Posner MR. Cancer of the Head and neck Region. In Skarin AT, editor. Atlas of Diagnostic oncology: Mosby; 2003. p. 27-61.
18. **Colevas A**, Scharf O, Vereshchagina L, Dancey J, Ivy S, Neckers L, Kaufman B, Swerdlow R: New Targets for Anticancer Therapeutics, in Chabner, Longo (eds): Cancer Chemotherapy and Biotherapy. Philadelphia, Lippincott Williams and Wilkins, 2006, pp 549-578.
19. Vereshchagina L, Scharf O, Colevas A: Investigational Anticancer Agents Targeting the Microtubule, in Fojo A (ed): Cancer Drug Discovery and Development: Microtubule Targets in Cancer Therapy. Totowa, Humana Press Inc., 2007

Selected Abstracts:

20. Van Voorhees LB, Goldstein SA, **Colevas AD**, Lindsay J. Prognostic significance of pericardial effusions in endocarditis: Identification by two-dimensional echocardiography. Clin Res 1984; 32:213a.
21. **Colevas AD**, Iliopoulos O, Kaelin WG. Tumor suppression and elongin binding by mutant von Hippel-Lindau proteins (Meeting abstract). Proc Annu Meet Am Assoc Cancer Res. 1996;37:A4091.
22. Iliopoulos O, **Colevas AD**, Kaelin WG. Functional analysis of the von Hippel-Lindau protein (Meeting abstract). Proc Annu Meet Am Assoc Cancer Res. 1996;37:A4072.

23. John Goffin MD, Len Appleman MD PhD, David Ryan MD, Panos Fidas ND, Joan Lucca RN MSN, Eileen Regan RN MSN, **A Dimitrios Colevas MD**, Joseph Paul Eder MD, Jeffrey Supko PhD, Geoffrey Shapiro MD PhD . A Phase I Trial of Gemcitabine followed by Flavopiridol in Patients with Solid Tumors Abstract for the Vancouver 10th World Conference on Lung Cancer, Aug 10-14, 2003
24. T. S. Garimella, M. J. Edelman, J. J. Horn, **A. D. Colevas** , K. S. Bauer. *In Vitro* Metabolism of the Novel Antimicrotubule Agent Benzoylphenylurea (BPU) Currently Under Phase I Investigation in Patients with Advanced Malignancy. American Association of Pharmaceutical Scientists annual meeting 2003, Salt Lake City.
25. **A. D. Colevas**, A. Setser. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. 2004 ASCO Annual Meeting. abstract 6098.
26. M. A. Shah, J. Kortmansky, M. Gonen, A. Tse, R. Lefkowitz, D. Kelsen, **D. Colevas**, J. Winkelman, S. Yi, G. Schwartz. A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F). 2004 ASCO Annual Meeting abstract 4027.
27. A. C. Pavlick, M. Millward, K. Farrell, A. Hamilton, A. Broseus, N. Haas, T. Shore, A. Jacquotte, **D. Colevas**, F. Muggia. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM). 2004 ASCO Annual Meeting. Abstract 7542.
28. M. Hussain, J. Faulkner, U. Vaishampayan, P. Lara, D. Petrylak, **D. Colevas**, W. Sakr, E. D. Crawford. Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111). 2004 ASCO Annual Meeting abstract 4510
29. T. Chen, A. Molina, S. Moore, S. Goel, K. Desai, A. Hamilton, T. Griffin, **A. D. Colevas**, S. Mani, F. Muggia. Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers. 2004 ASCO Annual Meeting abstract 2115.
30. T. S. Lin, J. T. Dalton, D. Wu, B. Fischer, M. Moran, D. Lucas, K. Cunningham, **A. D. Colevas**, M. R. Grever, J. C. Byrd. Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-hr continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL). 2004 ASCO Annual Meeting abstract 6564.
31. T. W. Synold, J. Lawrence, B. Xi, **A. D. Colevas**, M. D. Lewis, J. H. Doroshow. Human pharmacokinetics of E7389 (Halichondrin B analog), a novel anti-microtubule agent undergoing phase I investigation in the California Cancer Consortium (CCC). Proc Am Soc Clin Oncol 22: page 144, 2003 (abstr 575)

32. M. J. Edelman, K. S. Bauer, T. Meiller, N. Porter, N. Nemieboka, J. Desanto, **D. Colevas**. Phase I, pharmacokinetic (PK) and pharmacodynamic study of benzoylphenylurea (BPU, NSC 639829), a novel antitubulin agent. Proc Am Soc Clin Oncol 22: page 137, 2003 (abstr 550).
33. Michelle A. Rudek, Ming Zhao, Yelena Zabelina, Gurulingappa Hallur, Saeed Khan, Kenneth S. Bauer, Jr., **A. Dimitrios Colevas**, Antonio C. Wolff, and Sharyn D. Baker. *In vitro* and *in vivo* assessment of the metabolism of N,N-dimethylamino-benzoylphenylurea (BPU) in humans 2003 AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics Abstract Number: B247
34. Michelle A. Rudek, Nicola F. Smith, Ming Zhao, Ping He, Erin R. Leper, William D. Figg, **A. Dimitrios Colevas**, Sharyn D. Baker, Alex Sparreboom. Modulation of N,N-dimethylamino-benzoylphenylurea (BPU) absorption by the CYP3A and ABCG2 inhibitor ritonavir. 2004 AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics abstract 520.
35. D. Sullivan, R. Lush, L. Mahany, A. Dellaportas, A. Scuto, A. Daud, **D. Colevas**, K. Bhalla. A phase 1 study of Etoposide B analog BMS-247550 in combination with carboplatin in recurrent and/or refractory solid tumors. 2004 AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics abstract 536.
36. Lin TS, Fischer B, Moran ME, Lucas DM, Shank RS, Kraut EH, Farag SS, Lucas MS, **Colevas AD**, Grever MR, Byrd JC Phase I dose escalation study of flavopiridol in combination with fludarabine and rituximab: Activity in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma. BLOOD 104 (11): 2492 Part 1 NOV 16 2004
37. Byrd JC, Lin TS, Dalton JT, Wu D, Fischer B, Moran ME, Blum KA, Shank RS, Lucas DM, Lucas MS, Suarez JR, **Colevas AD**, Grever MR Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia (CLL) BLOOD 104 (11): 341 Part 1 NOV 16 2004
38. Steven Grant, Judith E. Karp, Omer N. Koc, Brenda Cooper, Selina Luger, William D. Figg, Merrill Egorin, Brian J. Druker, James W. Jacobberger, Viswanathan Ramakrishnan, Edward B. Perkins, **A. Dimitrios Colevas**, and John D. Roberts Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies. Blood (ASH Annual Meeting Abstracts), Nov 2005; **106**: 1102.
39. Judith E. Karp, B. Douglas Smith, Jacqueline Greer, Janet Briel, Mark J. Levis, Michael A. McDevitt, Steven D. Gore, and **A. Dimitrios Colevas** . A Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias. Blood (ASH Annual Meeting Abstracts), Nov 2005; **106**: 2784.

40. Steven Grant, Daniel Sullivan, David Roodman, Robert Stuart, Edward B. Perkins, Viswanathan Ramakrishnan, John Wright, **A. Dimitrios Colevas**, John D. Roberts. Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms. ASH annual meeting 2005 abstract # 3338.
41. T. W. Synold, R. J. Morgan, E. M. Newman, H. J. Lenz, D. R. Gandara, **A. D. Colevas**, M. D. Lewis, J. H. Doroshov. A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. ASCO annual meeting 2005 abstract # 3036
42. B. C. Widemann, E. Fox, W. J. Goodspeed, A. Goodwin, M. Cohen, T. Fojo, **A. D. Colevas**, F. M. Balis. Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors. ASCO annual meeting 2005 abstract # 8529
43. B. A. Conley, E. Donovan, C. Muir, J. Morris, **A. D. Colevas**, D. Gius, E. Trehu, E. Sausville, J. Wright, C. Vanwaes. Proteasome inhibitor bortezomib & re-irradiation (rRT) with scheduled treatment break in patients (pts) with head/neck squamous carcinoma (HNSCC). ASCO annual meeting 2005 abstract 5592
44. O'Connor, D. Straus, C. Moskowitz, P. Hamlin, C. Portlock, J. Gerecitano, E. Neylon, **D. Colevas**, A. Zelenetz. Targeting the microtubule apparatus in indolent and mantle cell lymphoma with novel epothilone analogue BMS 247550 induces major and durable remissions in very drug resistant disease. ASCO annual meeting 2005 abstract 6569.
45. Posadas E, Undevia S, **Colevas A**, Manchen E, Vokes E, Stadler W. A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma. . Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14646 2006;24(18s):14676.
46. Heath E, Alousi A, Eder J, Valdivieso M, Vasist L, Appleman L, Bhargava P, **Colevas A**, Lorusso P, Shapiro G. A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 2026 2006.
47. Lin T, Fischer B, Moran M, Shank R, Kraut E, Porcu P, Farag S, Blum K, **Colevas A**, Grever M, Byrd J. Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7599 2006.
48. Phelps M, Wu D, Byrd J, Lin T, Blum K, Schaaf L, Johnson A, **Colevas A**, Grever M, Dalton J. Pharmacokinetic and pharmacodynamic correlations of flavopiridol in the treatment of chronic lymphocytic leukemia. Journal of Clinical Oncology, 2006

ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 12000 2006.

49. Byrd J, Lin T, Dalton J, Phelps M, Fischer B, Moran M, Blum K, Rovin B, **Colevas A**, Grever M. Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 6516 2006.
50. Blum W, Klisovic R, Kefauver C, Johnson A, Phelps M, Dalton J, Lucas D, **Colevas A**, Grever M, Marcucci G, Byrd J. Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 6568 2006.